Practical Guidance on New Immuno-Oncology Strategies for Renal Cell and Urothelial Carcinoma

In these downloadable slidesets and clinical practice aids from our Chicago satellite, M. Dror Michaelson, MD; Sumanta Kumar Pal, MD; and Elizabeth R. Plimack, MD, MS; provide their expert insights on the clinical rationale and optimal integration of immunotherapy in to the clinic for patients with advanced urothelial or renal cell carcinoma.
M. Dror Michaelson, MD, PhD
Sumanta Kumar Pal, MD
Elizabeth R. Plimack, MD, MS

Downloadable Slideset

In this downloadable slideset, M. Dror Michaelson, MD, PhD, explores the data and clinical guidelines on the optimal use of immune checkpoint inhibitors for treating renal cell carcinoma.

M. Dror Michaelson, MD, PhD Sumanta Kumar Pal, MD Elizabeth R. Plimack, MD, MS Released: June 7, 2017

In this downloadable slideset, Elizabeth R. Plimack, MD, MS, discusses the data and clinical guidelines on the optimal use of immune checkpoint inhibitors for treating advanced urothelial cell carcinoma.

M. Dror Michaelson, MD, PhD Sumanta Kumar Pal, MD Elizabeth R. Plimack, MD, MS Released: June 7, 2017

In this downloadable slideset, Sumanta Kumar Pal, MD, addresses the management of adverse events associated with immune checkpoint inhibitors for optimal outcomes in patients with advanced urothelial cell and renal cell carcinoma.

M. Dror Michaelson, MD, PhD Sumanta Kumar Pal, MD Elizabeth R. Plimack, MD, MS Released: June 7, 2017

Clinical Resources

Download this pocket guide for information on dosing, administration, and clinical management for the current FDA-approved checkpoint inhibitor, nivolumab, in advanced RCC. This pdf includes a checklist for assessing your patients for common immune-related adverse events in the clinic.

M. Dror Michaelson, MD, PhD Sumanta Kumar Pal, MD Elizabeth R. Plimack, MD, MS Released: May 24, 2017

Download this a comprehensive pocket guide with dosing and administration information for currently FDA-approved checkpoint inhibitors in urothelial carcinoma. This guide also includes a checklist for detecting common immune-related adverse events in your patients receiving these agents.

M. Dror Michaelson, MD, PhD Sumanta Kumar Pal, MD Elizabeth R. Plimack, MD, MS Released: May 25, 2017
Jointly sponsored by National Comprehensive Cancer Network® (NCCN®) and Clinical Care Options, LLC.
NCCN Logo

Karen Kanefield
Manager CE Accreditation & Program Operations
National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462

215-690-0239
215-690-0283 (Fax)
gianola@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

Supported by an independent medical education grant from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?